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Objectives. To conduct a qualitative exploration of the lived experience of insomnia
disorder and its management amongst a sample of mixed-diagnoses cancer survivors.
Methods. Twenty-seven cancer survivors with persistent insomnia were recruited to
this qualitative study following completion of treatment for breast (12), prostate (7),
colorectal (7), and gynaecological (1) cancers. Eleven males and 16 females (mean age
62 years), who met DSM-5 criteria for insomnia disorder, contributed to one of four
focus group discussions, designed to explore the lived experience of persistent insomnia
and its management within cancer care services.
Results. Poor sleepwas a persistently troubling complaint for participants, long after the
completion of active cancer treatment. The impact of insomnia was significant for all
participants, with six key domains emerging as those most affected: temperament,
sociability, physical well-being, cognitive functioning, relationships, and psychological well-
being. In terms of insomnia management, participants frequently resorted to unfruitful
self-management strategies, due to the lack of professional insomnia expertise within
cancer care settings. Three main themes emerged in relation to insomnia management:
self-management, seeking professional intervention, and a lack of focus on sleep. A lack of
clinician understanding of the importance of sleep health and the poor availability of
evidence-based insomnia interventions, such as cognitive behavioural therapy for
insomnia (CBT-i), were highlighted as important gaps in cancer care.
Conclusions. Insomnia was found to have a detrimental and pervasive impact on cancer
survivors’ quality of life, which persisted long into survivorship. There is an absence of
professional attention to sleep throughout the cancer care trajectory, contributing to its
prevalence, persistence, and impact. In order to break this cycle, sleep health should be
integrated as a key aspect of cancer treatment and rehabilitation, much like maintaining a
healthy diet and appropriate levels of physical activity.
Statement of contribution
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 Insomnia is up to three times as prevalent in cancer survivors than in the general population.
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 Persistent insomnia is a recognized risk factor for the development of physical and mental ill health.
 Cognitive behavioural therapy is the gold standard insomnia treatment, but is rarely available to
cancer survivors
What does this study add?
 A comprehensive, qualitative account of the lived experience of insomnia disorder from the
patient’s perspective. This subjective experience is under-reported in the literature.
 Unfruitful self-management strategies are commonly utilized by cancer survivors who are living
with insomnia disorder.
 A life-course perspective on cancer survivorship is vital to ensure that emotional and psychological
well-being are prioritized during cancer rehabilitation.
Background
Despite the global increase in cancer rates, recent developments in detection and
treatmentmean that cancer survival has doubled in the last 40 years (Irwin, 2013; Stanton,
Rowland, & Ganz, 2015). Such progress has led to a considerable number of cancer
survivors requiring ongoing support for persistent cancer-related physical and psycho-
logical side effects, with numbers expected to increase with an ageing population
(Peoples et al., 2017; Zhou, Michaud, & Recklitis, 2020). Across various cancer groups,
the co-occurrence of symptoms such as sleep disturbance, pain, fatigue, low mood,
anxiety, and reduced quality of life (QoL) has been reported (Ho, Rohan, Parent, Tager, &
McKinley, 2015; Wu & Harden, 2015). Around one third of cancer survivors report the
persistence of such symptoms following the cessation of active cancer treatments (Savard,
Ivers, Villa, Caplette-Gingras, &Morin, 2011), placing a significant burden on both cancer
survivors and the health care system (Savard et al., 2011).
People with cancer are disproportionately affected by insomnia relative to the general
population (Garlandetal., 2014). In thegeneralpopulation,prevalence ratesofacutesleep
disturbance are estimated at around 30–40%, with around a 10% rate of chronic insomnia
(Ellis,Gehrman, Espie, Riemann,&Perlis, 2012).Disturbed sleep is estimated to affect 70%
of cancer patients,with 18–29% reporting sleep disturbance thatmeets diagnostic criteria
for insomnia disorder (Savard et al., 2011). Insomnia is diagnostically definedby theDSM-5
as difficulty with sleep initiation, maintenance, and/or non-restorative sleep with
associated impairment or significant distress (American Psychiatric Association, 2013).
Once established, insomnia commonly develops an unremitting and chronic course
(Schieber et al., 2019) and has often been described by cancer survivors as being more
challenging than cancer diagnosis and subsequent treatment (Palesh et al., 2010).
Thedevelopmentofchronic insomnia isproblematic sincepersistentsleepdisturbance
may be associated with considerable risk of further morbidity and mortality in cancer
patients (Andersen,Goyal,Westbrook,Bishop,&Carson,2017). Indeed,rather thansimply
being viewed as a symptom of cancer, insomnia is now widely regarded to be an
independentriskfactor for thedevelopmentofphysicalandmental illhealth(Peoplesetal.,
2019). It has been associated with a twofold increase in the risk of depression (Cha et al.,
2017), with emerging evidence suggesting that insomnia may actually have temporal
precedence to the onset of depressive disorders (Irwin, Olmstead, Ganz, & Haque, 2013).
Furthermore, insomniamayconfer risk forpoorercanceroutcomesbyadversely impacting
immunity and influencing tumour growth and progression (Irwin et al., 2013).
The aetiology of insomnia is complex and multifaceted, particularly in relation to
cancer (Fleming et al., 2019). Spielman’s 3P model (Spielman, Caruso, & Glovinsky,
2 Paul Reynolds-Cowie and Leanne Fleming
1987), outlining the development andmaintenance of insomnia, posits that pre-disposing,
precipitating, and perpetuating factors all contribute to the onset and persistence of
insomnia (Spielman et al., 1987). Pre-disposing factors such as age and gender, mainly
being older and female, for example, place some individuals at an elevated risk of
developing insomnia (Espie et al., 2008). The onset of insomnia is then precipitated by a
stressful life event, such as bereavement, relationship breakdown, or diagnosis of a serious
illness (Davis &Goforth, 2014). For cancer patients, reduced daytime activity and the side
effects of treatment such as increased fatigue can further elevate the risk of developing
persistent insomnia (Zhou, Suh, Youn, & Chung, 2017).
For many people, disturbed sleep is a normal psychological response to a life stressor
such as a cancer diagnosis, which occurs acutely, often self-resolving following
adjustment to their diagnosis, or remission of cancer following treatment (Garland
et al., 2014). However, approximately 18–29% of cancer patients develop a persistent
sleep problem that fails to self-resolve following completion of active cancer treatment
(Savard et al., 2011). This is often as a result of maladaptive coping behaviours being
enacted to compensate for sleep loss, which become entrenched and persist after cancer
remission (Fleming et al., 2019). Alterations to behaviour such as daytime napping,
irregular sleep–wake schedules, spending excessive time in bed, and worrying about the
impact of insomnia on overall well-being and recovery from cancer are all commonly
reported (Garland et al., 2014). This pattern of behaviour and thinking about sleep tends
to increase physiological, cognitive, and emotional reactivity at bedtime, creating a state of
conditioned arousalwhich is counter to the state of relaxation required for sleep initiation
and serves to perpetuate insomnia disorder (Perlis, Giles, Mendelson, Bootzin, & Wyatt,
1997).
Despite the prevalence and potential impact of cancer-related insomnia, its manage-
ment in clinical care remains suboptimal (Zhou, Clark, Recklitis, Obenchain, & Loscalzo,
2018). It is often presumed by both clinicians and cancer patients to be a transient
response to cancer diagnosis and treatment that will ultimately self-resolve (Schieber
et al., 2019). Consequently, insomnia is not routinely screened for in cancer clinics and is a
subject that patients rarely discuss with their oncology team (Coles et al., 2017; Schieber
et al., 2019). Evidence suggests that clinicians perceive themselves to be inadequately
trained or qualified to assess and treat sleep disturbance in cancer patients, reducing the
likelihood that it will be on the agenda during clinic appointments (Johnson et al., 2016;
Schieber et al., 2019).
Hypnoticmedications, in conjunctionwith sleep hygiene education, are presently the
most frequently utilized approach to treating cancer-related insomnia according to
research conducted in US cancer care centres (Zhou et al., 2018). Sleeping medication is
only designed for use with acute sleep disturbance and is also associated with negative
side effects such as dependence and tolerance, as well as being undesirable to many
cancer patients (Garland et al., 2014; Savard & Savard, 2013). An alternative non-
pharmacological treatment approach known as cognitive behavioural therapy for
insomnia (CBT-i) has accumulated a substantial evidence base as an efficacious and
durable therapy for insomnia (Ballesio et al., 2018) and is nowwidely regarded as the gold
standard treatment for persistent insomnia in the general population (Ballesio et al.,
2018).
Cognitive behavioural therapy for insomnia is a brief, sleep-focused, multimodal
intervention that targets the aspects of insomnia that are most amenable to change, such
as maladaptive sleep behaviours and faulty sleep cognitions (Zhou et al., 2017). CBT-i
comprises five potential elements, including stimulus control, sleep restriction, sleep
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hygiene, cognitive restructuring, and relaxation training. Evidence demonstrates that
CBT-i can be successfully administered using a range of delivery methods, including
groups (Jansson & Linton, 2005; Verbeek, Konings, & Aldenkamp, 2006), telephone
(Bastien, Morin, Ouellet, Blais, & Bouchard, 2004), online (Espie et al., 2013; Vincent &
Lewycky, 2009), and self-help manuals (Mimeault & Morin, 1999). Importantly, the
effectiveness of CBT-i has been demonstrated for insomnia that occurs alongside medical
conditions such as cancer,without the need tomodify the core aspects of the intervention
(Espie et al., 2008).
The efficacy of CBT-i iswell established in cancer survivors (Johnson et al., 2016) and is
a treatment that has highpatient acceptability (Davidson, Feldman-Stewart, Brennenstuhl,
& Ram, 2007). Several randomized controlled trials have demonstrated its efficacy in
improving insomnia symptoms in cancer survivors (Espie et al., 2008; Matthews et al.,
2014; Savard, Simard, Ivers, &Morin, 2005). A recent systematic reviewof eight controlled
and four uncontrolled trials of CBT-i in cancer survivors demonstrated large effect sizes for
self-reported insomnia severity for those who received CBT-i, compared to those who did
not (Johnson et al., 2016). Furthermore, CBT-i has also been found to have the potential to
have a positive impact beyond simply improving sleep, with secondary benefits in mood
(Peoples et al., 2019), fatigue (Fleming, Randell, Harvey, & Espie, 2014; Heckler et al.,
2016), and QoL (Fleming et al., 2014; Peoples et al., 2017). Additionally, CBT-i-based
interventions that specifically target other cancer-related symptoms, such as hot flushes
and night sweats, have shown promise (Mann et al., 2012).
Despite current and emerging evidence to support the use of CBT-i in addressing sleep
disturbance in cancer patients and survivors, challenges remain regarding its accessibility
in cancer care (Savard & Savard, 2017). A lack of adequately trained clinicians (Zhou et al.,
2017), being time-intensive relative to pharmacological treatments (Zhou et al., 2018),
and people having to travel long distances to access the intervention (Savard & Savard,
2017) are commonly cited barriers to its wider dissemination. Numerous research studies
have investigated methods of overcoming these concerns in cancer care and have
demonstrated the efficacy of CBT-i in online digital formats (Zachariae et al., 2018), video
format (Savard, Ivers, Savard, &Morin, 2016), brief adapted versions of the standard CBT-i
protocol (Casault, Savard, Ivers, & Savard, 2015), and when delivered by non-CBT
specialists such as oncology nurses (Dean et al., 2019; Espie et al., 2008). Indeed, the
clinical improvement in insomnia symptomatology demonstrated by these different
modes and intensities of treatment suggests that CBT-i could be incorporated as part of a
standardized and structured stepped care approach to the treatment of cancer-related
insomnia (Zhou et al., 2020). CBT-i is presently the recommended treatment for persistent
insomnia according to NICE guidelines in the United Kingdom (National Institute for
Health & Care Excellence, 2015). However, there is currently a lack of research on how
best to deliver sleep interventionswithin cancer care. There is also a lack of clarity around
the optimal timing of sleep interventions in order to achieve maximum therapeutic
benefit for individuals suffering from the effects of cancer-related insomnia.
This study qualitatively explores the lived experience of insomnia in a cohort of cancer
survivors. Themain objectives of this study are (1) to investigate the impact of insomnia on
cancer survivors’ lives, (2) to provide insight into the strategies usedby cancer survivors to
self-manage insomnia, (3) to explore the attention given to sleep difficulties throughout
the cancer care trajectory, and (4) to consider the availability of support or interventions
for sleep that are available to cancer survivors.
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Methods
Participants
Criteria for inclusion in this study were (1) a diagnosis of breast, colorectal, prostate, or
gynaecological cancer, (2)DSM-5diagnostically defined chronic insomnia, (3) completion
of active cancer treatment by at least 1 monthwith no further anticancer therapy planned
(thus excluding transient sleep effects associated with cancer treatment), and (4) aged
18 years or over. Exclusion criteria were (1) short-term or acute insomnia, <3-month
duration and (2) evidence of another sleep disorder (e.g., sleep apnoea). Potentially
eligible participants were identified by clinical teams at oncology outpatient clinics at the
BeatsonWest of Scotland Cancer Centre in the United Kingdomover a 6-month period. In
total, 54 potential participants were contacted by letter asking if they would like to take
part in a focus group discussion to explore (1) the impact of poor sleep on QoL and (2)
ways in which insomnia is managed. A consent form and participant information sheet
were also enclosed, providing further details about the purpose and nature of the study. A
total of 27 individuals responded, providing written consent. Those participants were
then contacted by the study researchers and were screened for eligibility by the
researchers using standard screening procedures. All participants met DSM-5 criteria for
insomnia, with no indication of the presence of other sleep disorders, and were thus
deemed eligible for the study. Participant demographic details are provided in Table 1.
Procedure
The use of focus groups was considered as an appropriate approach. Alongside being an
efficient means of data collection, focus groups permit participants to identify topics that
are important to them and to utilize their own frames of reference for discussion (Koffel,
Amundson, Polusny,&Wisdom, 2019). This approachpermits direct access to participant
experiences and perceptions. Each focus group lasted 90 min on average, which was
Table 1. Participant Demographics (all data are frequency exceptmean age/time since cancer diagnosis/
insomnia duration)















Mean time since cancer diagnosis (months) 34
Mean insomnia duration (months) 17
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agreed during consent, and participants were randomly allocated to one of four focus
groups. Once the groups were confirmed, participants were offered a range of times and
dates, and groups were organized based on times that suited everyone.
The groups consisted of 6, 7, 7, and 7 people, respectively. The focus group
discussions were facilitated by a research psychologist and a post-graduate psychology
student. The focus group topic schedulewas developedusing published literature and the
research team’s previous experience.
Participants were asked to respond to questions on the following topics:
1. the timing of insomnia onset
2. precipitating factors for its development
3. the impact of their sleeping pattern
4. management strategies to compensate for poor sleep.
The following questions were used to stimulate focus group discussion:
1. When did you start to sleep poorly?
2. What do you think caused your insomnia?
3. What impact did insomnia have on your life?
4. When did you become concerned about your sleep?
5. What did you do to try and resolve your insomnia?
6. What professional help or support were you offered to manage your insomnia?
All participantswere given the opportunity to respond fully to all questions, and group
discussion was encouraged and supported. At the end of each session, the facilitator
provided a verbal summary of themain topics and issues highlighted during the discussion
and asked the participants to confirm this as an accurate account. Immediately following
each of the sessions, the facilitators held a debriefing meeting in order to discuss and
record the main topics that emerged during the focus groups. The facilitators then
generated summary sheets of the content of the focus groups and these were sent to each
of the participants, the purpose of which was to ensure that the summary notes were an
accurate reflection of their discussion. These summary notes were checked, agreed,
signed, and returned by all participants.
Analysis
Focus groups, data collection, and analyses were concurrent. Once all focus groups had
been conducted and initial analyses had been undertaken, it became clear that no new
topics were emerging from the data. All focus group sessions were audio-recorded and
were transcribed verbatim. Thematic analysis was used to systematically analyse the data
produced in accordance with Braun and Clarke’s guidelines (Braun & Clarke, 2006). Five
key steps were undertaken during data analysis. First, the lead author familiarized
themselveswith the data by reading and re-reading the transcripts. An inductive approach
to analysis was employed. Initial ideas and impressions relating to the research objectives
werenoted andhighlighted, allowing the researcher to develop a thoroughunderstanding
of the data. Second, initial codes were constructed comprising brief descriptions of the
concepts identified from the data. These coded data were then arranged semantically.
Initial potential themes were extracted from the coded data and were reviewed in
consultationwith the co-author to assess appropriateness of the themes and the relevance
of coded data. Differences in opinions were resolved by discussion. Finally, the extracted
data were arranged into tables and themes were labelled. During the process of theme
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generation, particular attentionwas paid to both thewords used by participants and to the
context in which the participants expressed themselves.
Results
The impact of insomnia was significant for all participants. Indeed, many (n = 18)
reported that the consequences of poor sleep were often more overwhelming than the
impact of cancer treatment. Insight was also provided into the means by which
participants attempted to manage their insomnia. Overall, nine main themes emerged
from the analysis. The first six themes related to the impact of insomnia, whilst the final
three themes captured the processes involved in insomnia management. Themes and
subthemes related to the impact of insomnia are presented in Table 2.
I don’t feel like myself
A significant change in personality and temperament, feelings of guilt, and persistently
low motivation were frequently reported following the onset of sleep disturbance.
Participants described ‘massive guilt about feeling tired all of the time’, and in general
‘constantly feeling guilty’ about the impact poor sleep was having on their daily
functioning and ability to relate to others. Indeed, these changes impacted on close
personal relationships with people becoming ‘irritable’, ‘snappy’, ‘grumpier’, and
Table 2. Themes and subthemes related to the impact of insomnia
Theme Subthemes






Planning life around something uncontrollable Withdrawn/Isolated
Not making plans
Giving up work




My brain is not functioning Concentration
Memory
Keeping up with conversation
It’s more than just not sharing a bed Sleeping separately





Pressure to get back to normal
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‘intolerant’. These difficulties were compounded by a perception that significant others
did not understand or empathizewith such personality changes, and expected them to be
the person they were prior to their cancer diagnosis.
Many participants reported that their ‘QoL had gone out the window’, and they were
completely lacking in motivation. ‘So many things I remember not doing, things that I
wanted to do and things you put off until tomorrow, I can’t be bothered to do, I’m too
tired’. The pervasive impact of insomnia on all domains of functioning and sense of self
was evident throughout cancer survivors’ descriptions of their experiences and is well
summarized by one survivorwho said ‘you are not interested in anything really. . .it makes
you a bit depressed’.
Planning life around something uncontrollable
As highlighted in the previous theme, insomnia had a profound detrimental impact on the
ability to interact with others. This also extended into the domain of social functioning, as
poor sleep resulted in participants becoming increasingly withdrawn, avoidant, and
isolated. Some described becoming a ‘recluse’, with one stating that ‘I don’t mix with
peoplewhen I’vehad abadnight’s sleep’. Therewas a tendency tono longermakeplansor
commit to anything due to the unpredictable nature of sleep and concern that they might
be ‘bad tempered’withothers.Oneparticipant described it as being in ‘fear of having todo
something’. If plans were made for the following day, people would often unsuccessfully
attempt to get sufficient sleep by going to bed early. Indeed, one participant described
deciding whether they wanted to do something on ‘a tired day’ or not. Additionally, three
participants decided to give up work due to the impact of insomnia on their daily
functioning, with one describing it as being forced into retiring ‘basically because Iwas so
tired’. This theme effectively captures the feelings of helplessness and perceived loss of
control that can result from an inability to sleep well, with so many aspects of cancer
survivors’ social life being dictated by the quality of their sleep.
My body hurts
Sleep disruption had a considerable impact on physical well-being. Symptoms such as a
‘heightened pain level within your body’, ‘thumping headaches’, and feeling ‘physically
sick’ were reported by the majority of participants. They also highlighted how lack of
sleep tended to ‘exaggerate’ the experience of these difficulties. Furthermore, these
symptoms would often lead to reduced daytime activity and a tendency to engage in
behaviours such as daytime napping and increased caffeine intake to mitigate the effects
of insomnia. These physical symptoms andmaladaptive coping behaviours only served to
compound the aforementioned difficultieswith social interaction and overall functioning,
leaving participants stuck in the vicious insomnia maintenance cycle of poor night-time
sleep and impaired daytime functioning.
My brain is not functioning
Cognitive impairments were also frequently highlighted as a problematic consequence of
poor sleep. Forgetfulness, difficulty concentrating, and an impaired ability to follow
conversations in social and occupational settingsweremost common. These impairments
only served to exacerbate participants’ difficulties in social and interpersonal functioning,
in addition to precluding the enjoyment of previously pleasurable activities. The impact of
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the cognitive impairments outlined is well conceptualized by the following participant
description: ‘I can’t concentrate, I can’t hold a thought, I can’t rememberwhat that person
said to me three minutes ago. . .yeah, memory, concentration, conversations, sociability,
everything’s affected’.
It’s more than just not sharing a bed
Insomnia had a significant adverse impact on close and intimate relationships, beyond
simply being more irritable or less inclined to engage in social activities. A number of
participants reported sleeping in a different bedroom from their partner in order to avoid
disturbing them during periods of night-time wakefulness. This enforced separation
resulted in participants feeling that ‘their relationship had changed’ and that they ‘missed
out on conversations and making plans with their partners’ at bedtime or the following
morning. There was also a sense that therewere ‘many, manymore’ adverse influences of
insomnia on intimate relationships that were harder to articulate.
Worry
An all-consuming pre-occupation with sleep was reported by many participants. Racing
thoughts in bed, a feeling of their ‘imagination going into overdrive’, and catastrophizing
about the impact of poor sleep on daytime functioning were very common. Such
ruminative worry only serves to heighten psychological and physiological arousal that is
known to inhibit sleep onset. The stress associatedwith an increase in sleep effort in order
to feel able to cope with the day ahead is well illustrated by the following participant
extract:
It’s the stress of it. . .it’s the fact that you’re worrying about it, it’s how am I going to get up
tomorrowmorning, and how am I going to get out, and how am I going to get through work.
There was a patent and powerful sense of frustration at the persistence of sleep
difficulties, which was intensified by a feeling of pressure to return to ‘pre-cancer’ family
and occupational roles from others, who could not understand or empathize with the
pervasive impact of chronically disturbed sleep (Table 3).
Table 3. Cancer survivors’ perceptions of insomnia management
Theme Subthemes





I tried to get help GP
Sleeping tablets
Oncology team
Sleep is not on the agenda Sleep was never mentioned
No referral route
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I tried to help myself
Unsurprisingly, in the absence of any alternative, attempts to self-manage the impact of
insomnia through strategies such as daytime napping and time in bed extension were
common. Other methods employed included an evening wind-down routine, sleep
hygienepractices such as avoiding caffeine and chocolate later in the day, andusing herbal
remedies to aid sleep. Although some of these sleep hygiene strategies may have some
benefit, many of the self-management strategies reported by participants were
unsuccessful, increasing feelings of helplessness, worry, frustration, and anger.
I tried to get help
A significant proportion of participants raised the issue of poor sleep with their GP and
were offered a short-term prescription for sleeping medication (n = 13), which left many
feeling that this was ‘all that could be offered to you’. Others reported that they raised the
issue of poor sleep during routine cancer clinic appointments, only to be advised that it
was ‘nothing to do with treatment’. In addition, many survivors also mentioned that they
found the lack of treatment options ‘very depressing’. This is concerning and poses a
significant risk of cancer survivors feeling that disturbed sleep is a result of personal failing,
and has the potential to increase the feelings of hopelessness and helplessness that have
been discussed throughout. Many cancer survivors felt resigned to a persistent pattern of
chronic sleep disturbance being something that would never be resolved. Indeed, this is
exemplified by the participant who stated: ‘I’ve spoken to people that can’t sleep and I’ve
said, what have you done about it, but what can be done about it?’
Sleep is not on the agenda
It was reported that ‘no professional ever said to you, you might have sleep issues’, at any
point during cancer treatment or routine follow-up appointments. Many participants
reported feeling that clinicians were very reluctant to have any discussion around sleep,
and if patients didwant to discuss something thatwas not routine, or ‘on the agenda’, then
they were not particularly interested. However, they did caveat this by suggesting that it
may be partly due to professionals ‘having nowhere to refer you to’ and there ‘not being
anything helpful out there’. They also highlighted that being pre-emptively told that sleep
would likely become disturbed may have helped them to better understand and accept
their subsequent sleep difficulties. ‘If youwere told sleepwould be disrupted, particularly
during treatment then you might have accepted it’. Participants emphasized the need for
sleep to be discussed and assessed during cancer treatment and for clinicians to have a
referral route for those with sleep difficulties. This demonstrates the importance of sleep
health becoming a necessary, routine aspect of a holistic approach to cancer treatment
and rehabilitation.
Discussion
Insomnia commonly occurs during times of stress such as a diagnosis of cancer and is
amplified by the treatment process (Savard & Savard, 2013). The current study utilized a
qualitative approach to directly assess cancer survivors’ lived experience of insomnia, its
impact on daily functioning, and its management within cancer care. Concordant with
previous literature (Casault et al., 2015), cancer survivors experienced insomnia as a ‘24-
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hr disorder’, affecting sleep at night and daytime functioning. This had a pervasive and
chronic impact on several domains of functioning. The physical and psychological effects
of cancer-related insomnia and their detrimental influence on survivors’ QoL are evident.
The chronicity and persistence of these symptoms highlight the need for the implemen-
tation of sleep management protocols within cancer care clinics.
Participants’ perceptions of the management of insomnia were also explored.
Consistent with previous findings, routine sleep assessment was absent in cancer care,
and insomnia, when reported, was primarily treated with hypnotic medications (Coles
et al., 2017; Schieber et al., 2019). More alarmingly, all participants highlighted that sleep
was never discussed by clinicians and that they were never informed that disrupted sleep
was a common occurrence following cancer diagnosis and treatment. Informing cancer
patients that sleep disturbance is a normal response to cancer diagnosis and treatment
may help to reduce distress (Zhou et al., 2017), and offering sleep management guidance
may also help to prevent the development of a persistent sleep problem (Marion, Ivers, &
Savard, 2019).
Clinical implications
There is increasing acknowledgement within cancer care services that people diagnosed
with cancerwill spendmore time in survivorship care than in treatment (Garland,Mahon,
& Irwin, 2019) and that living longer following a cancer diagnosis does not necessarily
imply living well (Peoples et al., 2017). Many cancer survivors will spend months and
years recovering from the consequences of a cancer diagnosis and subsequent treatment
(Peoples et al., 2017). This has led to a shift in focus to optimizing the health of cancer
survivors, rather than simply disease treatment and symptommanagement (Garland et al.,
2019). Such an approach would be commensurate with advocates of lifeworld-led health
care, which emphasizes patient choice and involvement in their own care, as well as not
viewing health as simply the absence of illness (Dahlberg, Todres, & Galvin, 2009).
In the context of optimizing the long-term health of cancer survivors, the need for the
development of standardized assessment and treatment protocols for sleep disturbance
following cancer is evident. Indeed, in other areas of medicine, brief sleep medicine
traininghas been demonstrated to improve recognition and treatment of sleep apnoea, for
example (Valerio &Heaton, 2014). There is an increasing focus on preventative care with
cancer-related insomnia, and there have been some promising findings that such early
interventions offering sleep knowledge and educationmay have the ability to prevent the
onset of chronic sleep disturbance and reduce unhelpful beliefs about sleep, when
initiated prior to chemotherapy (Marion et al., 2019). Research in this area is still very
much in its infancy; however, normalizing sleep disturbance associated with cancer
diagnosis and treatment, and educating patients about ways to manage such difficulties
and improve sleep health, is certainly an important area for cancer services to further
develop (Zhou et al., 2017). It is also important to recognize that even if such preventative
measures could be incorporated into cancer care, the stress and side effects of treatment
mean that large numbers of cancer patientswill still require further input and intervention
for sleep disturbance (Savard & Savard, 2017).
There ismuch debate surroundingwhether it is possible to offer intervention for sleep
disturbance during active cancer treatment (Savard & Savard, 2017). Understandable
concerns have been raised that this may be too onerous a time for cancer patients to
engage with any cognitive behavioural sleep programme, especially whilst they are
attempting to manage the significant physical and psychological effects of cancer
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treatment (Zhou et al., 2017). Indeed, CBT-i is a very active treatment and places
considerable responsibility on the individual to elicit change through engaging with its
main recommendations, and active treatment may be an ill-advised time to attempt to
encourage engagement with such an approach (Savard & Savard, 2017). Furthermore,
intervening at thewrong time could increase the likelihood that patientswould disengage
with CBT-i and be less willing to re-engage further on in their cancer care journey (Zhou
et al., 2020).
The post-treatment survivorship phase should be given particular attention and may
also be an optimal time to offer therapeutic intervention for those suffering from
persistent sleep disturbance following cancer. Following treatment and cancer remission,
survivors often have less contact with health care services and diminished social support
and also very often feel a pressure to return to ‘normal life’, whilst still attempting to
manage a significant cancer-related psychosocial symptom burden (Wu&Harden, 2015).
Furthermore, given that cancer survivors are no longer having tomanage acute side effects
of anticancer treatments, this is likely to be a less burdensome time to attempt to
undertake active treatments such as CBT-I and may increase their efficacy (Savard &
Savard, 2017).
Greater attempts must also be made to improve the availability of efficacious non-
pharmacological interventions. CBT-i is now available for delivery in a number of different
modalities, helping to overcome previously cited concerns surrounding accessibility and
resource (Johnson et al., 2016). Indeed, this versatility in methods of delivery makes it
compatible with a stepped care approach to cancer-related insomnia care (Zhou et al.,
2017). Additionally, such attempts to offer CBT-i in a variety of formats have recognized
that help must be given to cancer care centres in accommodating these interventions,
when their primary role is to deliver cancer treatment (Zhou et al., 2020). It is clear that
sleep is a potentially fruitful therapeutic target to improve bothphysical andmental health
in cancerpatients and requires the development of protocols for it to be routinely assessed
and treated in cancer care. Indeed, the future development of preventative interventions
prior to cancer treatment may well help to reduce the prevalence of chronic insomnia in
cancer survivors and thus reduce the potential for further morbidity and mortality
associated with persistently disturbed sleep.
Study limitations
Measures such as using summary sign off sheets following focus groups to ensure the
topics coveredwere a fair reflection of participants’ accounts, thereby enhancing validity,
were employed to strengthen the study’s methodology. However, it is important to
acknowledge some limitations also. The study sample was not representative of all
individuals with cancer and sleep problems, limiting generalizability to the cancer
population as a whole. A selection bias in favour of people who feel comfortable
discussing their experiences and who are highly motivated to co-operate is assumed.
Using focus groupmethodologymay have limited the depth of information itwas possible
to obtain on the emotional experience of insomnia. Whilst all participants were
encouraged to contribute to the focus group discussion, we acknowledge that one-to-one
interviews may have allowed participants to discuss their lived experience of insomnia in
greater detail. Furthermore, it is also acknowledged that the researchers did not share the
experience of cancer-related insomnia with participants, and thus, this could have had an
influence on the interpretation of the experiences that were shared.
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Future research
Based on current research evidence, CBT-i is presently the only recommended treatment
for insomnia related to cancer (Johnson et al., 2016; Matthews, Carter, Page, Dean, &
Berger, 2018). Future research should seek to address the unanswered question of the
optimal time to intervene in cancer-related insomnia. Research at each stage of the cancer
trajectory, that is followingdiagnosis andprior to treatment, during treatment, and inpost-
treatment survivorship, is required. Increasing attention must be paid to the potential of
preventative interventions prior to treatment initiation and also interventions in the
immediate post-treatment phase, in an attempt to reduce the chronicity of cancer-related
insomnia. A need for research with a diversity of cancer types and also possibly adapting
CBT-i for cancer patients, to include elements of cancer symptommanagement, similar to
Mann et al. (2012), where they targeted hot flushes and night sweats, along with sleep
disturbance in breast cancer survivors, may also be worthwhile.
Aneed for improved awareness of sleepdisturbance amongst professionals involved in
cancer care is also necessary. Qualitative methodologies such as those employed in the
present study may help to shed light on the training needs of clinicians, as well as
providing insight into their views on the optimal intervention time for cancer-related
insomnia. Furthermore, cancer patients’ views would also be invaluable regarding both
the timing and method of intervention delivery. Patient preferences and expectations are
known to influence treatment outcomes, yet these are very rarely captured or reported in
clinical research (Mills et al., 2011).
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